Clarametyx Biosciences Inc has appointed four experts to its scientific advisory board to advance the clinical stage biotech’s anti-biofilm therapeutic pipeline for chronic respiratory disease. The experts bring extensive biologic, therapeutic and vaccine expertise, and are: Bruce Forrest, MD, a specialist in biopharmaceuticals and vaccines development and previously at Wyeth (now Pfizer); George Siber, MD, a developer of vaccines and antibody products and co-founder of Affinivax; Obadiah Plante, PhD, a leader in biotech, vaccines and infectious disease research and president at P5 Innovations; and C. David Zarley, PhD, with expertise in viral, bacterial and therapeutic vaccines and previously at Pfizer Vaccine Research and Development. The company’s lead asset, CMTX-101, has completed a Phase 2a study for cystic fibrosis-related, biofilm-driven infections.
Clarametyx Biosciences announced the appointments on 27 January 2026.
Copyright 2026 Evernow Publishing Ltd.